FDA Clears C2N Alzheimer Blood Test
Analysis based on 28 articles · First reported Aug 21, 2026 · Last updated Sep 21, 2026
FDA clearance of the PrecivityAD2 test expands the addressable market for blood-based Alzheimer's diagnostics, potentially benefiting C2N Diagnostics and its partners while pressuring makers of PET imaging and spinal fluid testing. Broader adoption of cheaper, less invasive testing could accelerate diagnosis and support demand for new Alzheimer's therapies, though near-term revenue impact remains limited by the test's narrow intended population.
The U.S. United States — Food and Drug Administration cleared the PrecivityAD2 blood test, developed by C2N Diagnostics, a startup founded by researchers at Washington University in St. Louis, to help evaluate Alzheimer's disease in adults aged 40 and older who already show signs of cognitive decline. The test uses high-resolution mass spectrometry to measure ratios of amyloid beta and tau proteins, offering a less invasive alternative to PET brain scans and lumbar punctures. FDA clearance was supported by a study of 1,142 adults with cognitive symptoms, in which the test showed a positive predictive value of 97.6% and a negative predictive value of 93.1% compared with established reference methods. The test is intended as a diagnostic aid alongside full clinical assessment, not as a standalone diagnosis or a screening tool for healthy people. Separate reporting highlights that four Alzheimer's blood tests have now been cleared, but experts including Nicholas Ashton of Banner Health caution that symptom-free individuals should avoid such tests outside research. Research led by Mass General Brigham found that cognitively healthy older adults with very high p-tau217 levels had a 38% risk of developing cognitive impairment within five years. A study led by Josef Coresh of NYU Langone Health found that people who reached middle age without high blood pressure, type 2 diabetes and smoking lived dementia-free nearly 13 years longer than those with all three conditions. Mark Yost, a 60-year-old study volunteer, received an intermediate result. The Alzheimer s Association and United States — National Institute on Aging provide context on prevalence and disease biology, while the Mayo Clinic notes risks of spinal taps.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard